{
    "eid": "2-s2.0-85123284043",
    "title": "Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Booster",
        "Clinical trial",
        "Inactivated vaccine",
        "MRNA vaccine",
        "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)",
        "Third dose",
        "Viral vector vaccine"
    ],
    "authors": [
        "Sitthichai Kanokudom",
        "Suvichada Assawakosri",
        "Nungruthai Suntronwong",
        "Chompoonut Auphimai",
        "Pornjarim Nilyanimit",
        "Preeyaporn Vichaiwattana",
        "Thanunrat Thongmee",
        "Ritthideach Yorsaeng",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Sirapa Klinfueng",
        "Natthinee Sudhinaraset",
        "Nasamon Wanlapakorn",
        "Sittisak Honsawek",
        "Yong Poovorawan"
    ],
    "citedby-count": 43,
    "ref-count": 43,
    "ref-list": [
        "The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data",
        "Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant",
        "Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study",
        "SARS-CoV-2 IgG antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (CoronaVac) at Phyathai 3 Hospital",
        "CoronaVac induces lower neutralising activity against variants of concern than natural infection",
        "Safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers",
        "Confronting the Delta variant of SARS-CoV-2, Summer 2021",
        "Delta to dominate world",
        "Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2",
        "Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine",
        "Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults",
        "Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine",
        "Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2",
        "Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine",
        "Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine",
        "Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals",
        "Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data",
        "Boosting immunity to COVID-19 vaccines",
        "China\u2019s COVID vaccines have been crucial\u2014Now immunity is waning",
        "Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study",
        "Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002)",
        "Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18\u201359 years: Interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial",
        "The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine",
        "Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers",
        "Immunogenicity and Safety of an Intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population",
        "Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults",
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial",
        "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
        "Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19",
        "IgA dominates the early neutralizing antibody response to SARS-CoV-2",
        "Humoral responses and serological assays in SARS-CoV-2 infections",
        "Human IgG and IgA responses to COVID-19 mRNA vaccines",
        "The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus",
        "A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation",
        "A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein",
        "Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern",
        "T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire",
        "BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans",
        "Heavily mutated Omicron variant puts scientists on alert",
        "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant",
        "Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "127614853",
            "affilname": "The Royal Society of Thailand (FRS(T))",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127614853",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Clinical Virology",
        "King Chula-longkorn Memorial Hospital",
        "Second Century Fund",
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Health Systems Research Institute"
    ]
}